



ABIVAX launches ABX464-004 study; First patient enrolled in second Phase IIa trial

May 30, 2016

Published on Monday, 30 May 2016 18:00

Paris, May 30th, 2016 - ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral therapies and immunotherapeutics for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that the first patient in the ABX464-004 study has been enrolled, effectively launching the second Phase IIa trial in HIV/AIDS patients with drug candidate ABX464. The first patient treatment in this trial is scheduled to take place at University Hospital Germans Trias i Pujol in Badalona, Barcelona, Spain. The trial will be conducted at clinical centers in Spain and Belgium, where all regulatory and ethics committees authorizations have been received, and in France where pending ethics committees approvals are expected imminently.